Nature Reviews Rheumatology, Published online: 19 November 2025; doi:10.1038/s41584-025-01321-xChildhood-onset SLE is characterized by high disease activity, severe organ damage and substantial treatment challenges. The authors of this Review provide an update on the advances in the understanding of the pathogenesis of childhood-onset SLE in the past decade, emphasizing the need for more research to improve outcomes.

Nature Reviews Rheumatology, Published online: 24 November 2025; doi:10.1038/s41584-025-01334-6The results of the phase II DAHLIAS trial support the development of the neonatal Fc receptor blocker nipocalimab for the treatment of Sjögren disease.

Nature Reviews Rheumatology, Published online: 24 November 2025; doi:10.1038/s41584-025-01326-6This Review explores the complex relationship between obesity and psoriatic disease. The authors highlight the underlying mechanisms that drive this association and propose a comprehensive approach to managing obesity in individuals with psoriatic disease to improve overall disease management and therapeutic response.

Nature Reviews Rheumatology, Published online: 18 November 2025; doi:10.1038/s41584-025-01330-wFindings reveal that inhibiting cytosolic phospholipase A2 in chondrocytes could be a potential therapeutic target for degenerative joint diseases.

Analysis of regional variations in the epidemiology of rheumatoid arthritis (RA) over the past 40 years indicates that the age-standardized incidence of RA has increased — and is expected to continue ...

Immune-mediated inflammatory diseases (IMIDs) are associated with cancer risk through mechanisms involving disrupted immune tolerance and dysregulated immune responses. Deng et al. investigated how th...

ANCA-associated vasculitis (AAV) includes three disease subtypes with partly overlapping clinical manifestations: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophili...

This Review article provides an update on the pathophysiology, diagnosis and treatment of Takayasu arteritis. The authors emphasize the need for a multidisciplinary approach to the diagnosis and manag...

This Review discusses latest advances in the field of cutaneous lupus, including the improved understanding of disease pathogenesis and emerging targeted therapies.

Nature Reviews Rheumatology, Published online: 19 November 2025; doi:10.1038/s41584-025-01321-xChildhood-onset SLE is characterized by high disease activity, severe organ damage and substantial treatment challenges. The authors of this Review provide an update on the advances in the understanding of the pathogenesis of childhood-onset SLE in the past decade, emphasizing the need for more research to improve outcomes.

Nature Reviews Rheumatology, Published online: 18 November 2025; doi:10.1038/s41584-025-01330-wFindings reveal that inhibiting cytosolic phospholipase A2 in chondrocytes could be a potential therapeutic target for degenerative joint diseases.

Nature Reviews Rheumatology, Published online: 13 November 2025; doi:10.1038/s41584-025-01323-9The factors and mechanisms that regulate osteoclast-induced inflammatory bone loss are complex. The authors of this Review provide an overview of osteoclast regulation in the context of inflammatory bone loss and rheumatoid arthritis and provide insights into potential treatment strategies.

Nature Reviews Rheumatology, Published online: 13 November 2025; doi:10.1038/s41584-025-01323-9The factors and mechanisms that regulate osteoclast-induced inflammatory bone loss are complex. The authors of this Review provide an overview of osteoclast regulation in the context of inflammatory bone loss and rheumatoid arthritis and provide insights into potential treatment strategies.

Nature Reviews Rheumatology, Published online: 07 November 2025; doi:10.1038/s41584-025-01322-wCirculating cell-free DNA (cfDNA) and cfDNA fragmentation signatures are emerging as promising non-invasive biomarkers for various indications, most notably cancer. New analysis of cfDNA fragmentation in autoimmunity highlights potential links to cancer, as well as the promise of these tools for improved understanding and clinical care of autoimmune disease.

Nature Reviews Rheumatology, Published online: 07 November 2025; doi:10.1038/s41584-025-01325-7A new population-based study suggests that sodium–glucose cotransporter-2 (SGLT2) inhibitors — originally developed for glycaemic control — reduce the risk of autoimmune rheumatic diseases.

Nature Reviews Rheumatology, Published online: 07 November 2025; doi:10.1038/s41584-025-01318-6This Review discusses latest advances in the field of cutaneous lupus, including the improved understanding of disease pathogenesis and emerging targeted therapies.

Nature Reviews Rheumatology, Published online: 06 November 2025; doi:10.1038/s41584-025-01309-7This Review article provides an update on the pathophysiology, diagnosis and treatment of Takayasu arteritis. The authors emphasize the need for a multidisciplinary approach to the diagnosis and management of this complex disease.

Nature Reviews Rheumatology, Published online: 06 November 2025; doi:10.1038/s41584-025-01319-5Within the framework of the UN Decade of Healthy Ageing, the World Health Organization has defined core indicators focused on timely hip-fracture management and secondary fracture prevention in people 60 years of age and over. This Perspective article examines the relevance and implementation of these indicators, and the implications of their adoption for equitable care of older people worldwide.

This Review discusses latest advances in the field of cutaneous lupus, including the improved understanding of disease pathogenesis and emerging targeted therapies.

Nature Reviews Rheumatology, Published online: 07 November 2025; doi:10.1038/s41584-025-01322-wCirculating cell-free DNA (cfDNA) and cfDNA fragmentation signatures are emerging as promising non-invasive biomarkers for various indications, most notably cancer. New analysis of cfDNA fragmentation in autoimmunity highlights potential links to cancer, as well as the promise of these tools for improved understanding and clinical care of autoimmune disease.

Nature Reviews Rheumatology, Published online: 07 November 2025; doi:10.1038/s41584-025-01325-7A new population-based study suggests that sodium–glucose cotransporter-2 (SGLT2) inhibitors — originally developed for glycaemic control — reduce the risk of autoimmune rheumatic diseases.